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In this issue of SAMJ, Mayosi and colleagues1 report the 
results of an observational study on the mortality rate and 
its predictors in patients with a presumptive diagnosis of 
tuberculous pericarditis in sub-Saharan Africa. By enrolling 
patients with presumed tuberculous pericarditis from 15 
referral hospitals in Cameroon, Nigeria and South Africa, 
and not insisting on gold-standard diagnostic criteria, the 
investigators have managed to enroll 185 patients within a 6-
month period between March and October 2004. Patients were 
eligible for enrolment if the attending physician felt sufficiently 
confident with the diagnosis of tuberculous pericarditis to 
commence antituberculosis treatment, and the management of 
each patient was at the discretion of the attending physician, 
in keeping with the observational nature of the study. In the 
majority of patients, HIV status was based on serological 
testing for HIV, but due to the fact that, at the time of the 
study, voluntary and confidential testing for HIV was not 
always offered at the participating medical institutions, the 
investigators included the category of suspected HIV infection 
based on clinical grounds, and classified each patient as either 
having evidence of ‘clinical HIV disease’ or ‘no clinical HIV 
disease’, without regard to the HIV serological status of the 
patient. The HIV assessment was left to the discretion of the 
collaborating physician, and no criteria were specified.
This approach may lack some scientific rigour but it allowed 
rapid enrolment of all suspected cases and reflects the real-life 
experience of clinicians across Africa who do not always have 
access to diagnostic facilities and who do not find it difficult to 
diagnose tuberculous pericarditis on clinical grounds, however 
difficult it may be to confirm the diagnosis in the laboratory.2,3 
Using Cox regression, they assessed the effect of baseline 
clinical and therapeutic characteristics on mortality during a 6-
month period of follow-up. In a group of 174 patients (median 
age 33; range 14 - 87 years), the overall mortality rate was 26%, 
and it was significantly higher in patients who had clinical 
features of HIV infection than in those who did not (40% v. 
17%, p=0.001). Independent predictors of death during follow-
up were: (i) a proven non-tuberculosis final diagnosis (hazard 
ratio (HR) 5.35, 95% confidence interval (CI) 1.76 - 16.25), (ii) 
the presence of clinical signs of HIV infection (HR 2.28, CI 
1.14 - 4.56), (iii) coexistent pulmonary tuberculosis (HR 2.33, 
1.20 - 4.54), and (iv) older age (HR 1.02, CI 1.01 - 1.05). There 
was also a trend towards an increase in death rate in patients 
with haemodynamic instability (HR 1.80, CI 0.90 - 3.58) and a 
decrease in those who underwent pericardiocentesis (HR 0.34, 
CI 0.10 - 1.19).
The strength of the study is that it reflects what clinicians 
experience in the field and what they perceive to be HIV- 
and tuberculosis-related deaths. This experience may differ 
substantially from statistics captured by national tuberculosis 
control programmes. This study by Mayosi and colleagues1 
demonstrates that a presumptive diagnosis of tuberculous 
pericarditis is associated with a high mortality in sub-Saharan 
Africans, and calls for attention to rapid aetiological diagnosis 
of pericardial effusion and treatment of concomitant HIV 
infection as this may reduce the high mortality associated with 
the disease.
Tuberculosis is an ancient disease, with evidence of spinal 
TB described in Neolithic man and clear evidence of TB bone 
lesions found in mummified remains from ancient Egypt. 
Initial infection is usually via the pulmonary route, following 
inhalation of an inoculum of organisms within tiny aerosol 
droplets, predominantly produced by adults with cavitary TB. 
Extrapulmonary tuberculous disease occurs as the result of 
contiguous spread of tubercle organisms to adjoining structures 
such as pleura or pericardium, or by lymphohaematogenous 
spread during primary or chronic infection. HIV infection 
increases the dissemination of TB particularly as the CD4 cell 
count declines below 200 cells/μl. Pericardial effusion is a 
frequent clinical finding in HIV-seropositive patients coinfected 
with TB in a variety of global settings.4-6
Tuberculous pericarditis most commonly results from direct 
extension from contiguous mediastinal and hilar lymph nodes 
or by lymphohaematogenous spread as part of disseminated 
TB. The clinical presentation of tuberculous pericarditis is vari-
able and includes acute pericarditis with or without effusion, 
cardiac tamponade, silent large pericardial effusion with a 
relapsing course, toxic symptoms with persistent fever, acute 
constrictive pericarditis, subacute constriction, or effusive-con-
strictive or chronic constrictive pericarditis.3,7 The mortality rate 
in untreated acute effusive tuberculous pericarditis approaches 
85%.7 The goal of therapy for tuberculous pericarditis is to pre-
vent death due to tamponade, to relieve the acute symptoms of 
cardiac compression, and to prevent progression from the effu-
sive to the constrictive stage, in which a fibrotic and calcified 
pericardium entraps the heart.8-10 The management of HIV 
coinfection is of utmost importance and should include cotri-
moxazole preventive therapy and provision of highly active 
antiretroviral therapy (HAART). Standard management of peri-
cardial effusion includes pericardiocentesis either by echocar-
diographically guided closed pericardiocentesis8,10 or by surgi-
cal fenestration.5,11 Recommended antituberculosis chemothera-
py for pericardial TB is the same as for pulmonary TB.8,11 The 
use of adjunctive corticosteroid therapy is controversial.8,10,12
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EDITORIAL
UCT Surgery Update 
Saturday 15 to Sunday 16 March 2008 
Groote Schuur Hospital, Cape Town, South Africa 
We invite you to attend the University of Cape Town Department of Surgery Update 
Conference 'Practical Solutions for Common Surgical Problems'. The programme is 
aimed at General Surgeons and Surgical Registrars as well as General 
Practitioners and Medical Officers with a surgical aspect to their practice.
The topics have been selected specifically to address common surgical problems 
and dilemmas faced in everyday surgical practice. The emphasis will be on 
relevant and up to date management of a broad range of general surgical issues. 
Presentations will be practical with evidence based advice.
Professor Derek Alderson, an upper gastrointestinal surgeon, from Birmingham, 
UK will be the guest speaker. 
The presentations will run from 8am Saturday 15 March to 4pm Sunday 16 March 
2008 to minimise disruption to private practice and other clinical duties.  
The conference will be CPD accredited. 
For programme, registration information and accommodation options,
please contact: 
UCT Conference Management Centre 
Barnard Fuller Building, UCT Faculty of Health Sciences, 
Anzio Road Observatory, 7925 Cape Town South Africa 
Tel: +27 21 406 6167 Fax: +27 21 448 6263 
Email: deidre.raubenheimer@uct.ac.za
Website: www.cmc.uct.ac.za
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